Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KD 382

Next Previous
Drug Profile

KD 382

Alternative Names: KD-382; Tetravalent dengue vaccine

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kaketsuken
  • Developer KM Biologics; Mahidol University
  • Class Attenuated vaccines; Dengue vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Dengue

Most Recent Events

  • 28 Jan 2025 KD 382 is still in phase I development for Dengue in Australia (Meiji Seika Pharma pipeline, January 2025)
  • 28 Apr 2024 No recent reports of development identified for phase-I development in Dengue(In volunteers) in Australia (SC, Injection)
  • 20 Apr 2022 KD 382 is still in phase I development for Dengue in Australia (Meiji pipeline, April 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top